Clinical trials: Body Weight Control
Ulcerative Colitis, Obesity or Overweight
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and…
- Trial name
- COMMIT-UC (NCT06937086)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 187 sites in United States, Austria and 21 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Efficacy and Safety of IQP-VV-102 in Weight Management
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored
- Trial name
- NCT01681069
- Testing
- IQP-VV-102
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo.
- Trial name
- VESPER-2 (NCT06897202)
- Testing
- MET097 Injection
- Where
- 29 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like birth control tablets, and emptying of the stomach in women not able to become pregnant living with…
- Trial name
- NCT07710729
- Testing
- UBT251, Oral contraceptive, Acetaminophen
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study of LY3532226 in Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity.
- Trial name
- NCT06557356
- Testing
- LY3532226
- Where
- 4 sites in United States, Singapore
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
- Trial name
- NCT07890870
- Testing
- IBIO-610
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
- Trial name
- NCT00391196
- Testing
- CP-945,598, CP-945,598 Treatment B
- Where
- 91 sites in United States, Argentina and 9 more
- Volunteers
- 975 people
- Sponsor
- Pfizer
Obesity
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like…
- Trial name
- NCT02692781
- Testing
- MOD-6031
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Obesity
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older.
- Trial name
- STRIDES (NCT06515418)
- Testing
- Oral Azelaprag (BGE-105), Tirzepatide
- Where
- 14 sites in United States
- Volunteers
- 204 people
- Sponsor
- BioAge Labs, Inc.
Growth Disorders, Dietary Exposure
Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns
This single-center, randomized controlled pilot study aims to evaluate the efficacy of TruHeight Growth Protein Shake on improving growth patterns in children aged 4-17 years.
- Conditions
- Growth Disorders, Dietary Exposure, Child Development, Bone Development Abnormal
- Trial name
- NCT06329388
- Testing
- TruHeight Growth Protein Shake
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TruHeight Vitamins
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
Taldefgrobep Alfa in Adults With Overweight and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
- Trial name
- NCT07281495
- Testing
- Taldefgrobep Alfa
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Biohaven Therapeutics Ltd.
Obesity and Type 2 Diabetes
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2…
- Trial name
- RESOLVE-1 (NCT07055516)
- Testing
- NT-0796
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rezera (formerly NodThera Limited)
Obesity, Women
Lactobacillus Gasseri and Hormonal Regulation in Obese Women
To evaluate the regulatory effect of Lactobacillus gasseri LG08 formula on visceral fat metabolism and sex hormone balance in obese women.
- Trial name
- NCT07502404
- Testing
- Probiotic, Maltodextrin
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Leptin Receptor Deficiency Obesity
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the…
- Trial name
- NCT03287960
- Testing
- Setmelanotide
- Where
- 6 sites in Canada, France and 4 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
- Trial name
- OLE (NCT00788528)
- Testing
- S-2367 (velneperit)
- Where
- 73 sites in United States
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications…
- Trial name
- NCT00339014
- Testing
- Zonisamide CR and Bupropion SR
- Where
- 15 sites in United States
- Volunteers
- 611 people
- Sponsor
- Orexigen Therapeutics, Inc
Type 2 Diabetes, Obesity
Blood Glucose Stability and Variability on Two Diets
This investigation will examine the effects of consuming a structured, portion-controlled, low-glycemic index diet (commercially available as the Nutrisystem-D program) on several indicators of glycemic stability and variability…
- Trial name
- NCT01443143
- Testing
- Portion-controlled diet, Usual Diet
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nutrisystem, Inc.